Résumés
Résumé
Contexte. Les personnes utilisatrices des drogues injectables (PUDI) vivent de la stigmatisation, de la discrimination, un faible soutien et des interactions difficiles avec les professionnels dans le système de soins. Cela entraîne un accès limité aux soins, notamment la prophylaxie préexposition (PrEP) contre le virus de l’immunodéficience humaine (VIH) et les nouveaux traitements d’hépatite C (HC). Les services de navigation peuvent améliorer l’accès à ces soins. Cette analyse documentaire vise à synthétiser les connaissances disponibles sur les expériences des PUDI avec les services de navigation liés à la PrEP et aux soins de l’HC.
Méthodes. Une recherche documentaire a été menée à partir de cinq bases de données et complétée par la vérification des listes de références et une recherche manuelle de la littérature grise. Les données pertinentes ont été extraites et synthétisées selon l’approche narrative. Un total de quatorze articles ont été inclus dans cette analyse documentaire.
Résultats. Les services de navigation analysés dans cette synthèse sont la colocation des soins dans les sites fixes ou mobiles, la référence externe à l’aide des intervenants et le soutien des pairs. Les bénéfices de ces services pour les PUDI ressortent de manière unanime. La colocalisation des soins semble la plus optimale grâce à la facilité, la rapidité d’accès aux soins ainsi que l’environnement familier et non stigmatisant pour les PUDI. La confiance établie avec les professionnels ainsi que l’importance des pairs ont aussi été relevées. Cependant, les difficultés antérieures dans le système de soins standard persistent.
Discussion. La colocalisation des soins dans les lieux non stigmatisants et une bonne relation de confiance avec les professionnels sont centrales pour l’expérience de navigation des PUDI liée à la PrEP et aux soins d’HC. D’autres études sont nécessaires pour approfondir les facteurs personnels et contextuels liés à l’expérience de navigation des PUDI.
Mots-clés :
- personnes utilisatrices de drogues injectables,
- services de navigation,
- prophylaxie pré-exposition,
- soins de l’hépatite C,
- expériences
Abstract
Context. People who use injection drugs (PWID) experience stigma, discrimination, lack of support, and difficult interactions with professionals in the care system. This results in limited access to needed care, including pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) and new hepatitis C (HC) treatments. Navigation services can improve access to such care among PWID. Thus, this review aims to synthesize the available knowledge on PWID’s experiences with PrEP and HC care-related navigation services.
Methods. A literature search was conducted using five databases, supplemented by checking reference lists and a manual search of the grey literature. Relevant data were extracted and synthesized using the narrative approach. A total of fourteen articles were included in this review.
Results. The navigation services analyzed in this synthesis are co-location of care in fixed or mobile sites, external referral with intervener assistance and peer support. The benefits of these services for PWID are unanimous.
Co-location of care seems to be the most optimal because of the ease and timeliness of access to care as well as the familiar and non-stigmatizing environment for the majority of PWID. Good trust with professionals and the importance of peers for PWID were also reported. However, previous difficulties in the standard care system remain.
Discussion. Co-location of care in non-stigmatizing settings and a good, trusting relationship with professionals is preferred by PWID in their navigation related to PrEP and HC care. But more studies are needed to further explore personal and contextual factors in PWID experience with navigation.
Keywords:
- PWID,
- navigation services,
- PrEP,
- HVC health care,
- experiences
Resumen
Contexto: Los usuarios de drogas inyectables experimentan estigmatización, discriminación, un apoyo débil e interacciones difíciles con los profesionales del sistema de salud. Esto significa que tienen un acceso limitado a la atención, principalmente en lo que respecta a la profilaxis preexposición contra el virus de la inmunodeficiencia humana (VIH) y los nuevos tratamientos para la hepatitis C. Los servicios de navegación pueden mejorar el acceso a estos cuidados, por lo que esta revisión apunta a sintetizar los conocimientos disponibles sobre las experiencias de quienes usan drogas inyectables con los servicios de navegación relacionados con la profilaxis preexposición y la atención de la hepatitis C.
Método: Se llevó a cabo una investigación documental a partir de cinco bases de datos, completada por la verificación de listas de referencia y una investigación manual de la literatura gris. Los datos pertinentes fueron extraídos y sintetizados siguiendo un enfoque narrativo. Un total de 14 artículos fueron incluidos en esta revisión.
Resultados: En esta síntesis se han analizado los servicios de navegación colocalizados en sitios fijos o móviles, la referencia externa por medio de agentes de intervención y el apoyo de los pares. Los beneficios de estos servicios para los usuarios de drogas inyectables se destacan de manera unánime. La colocalización de los cuidados parece ser óptima merced a la facilidad y la rapidez de acceso a la atención y al ambiente familiar y no estigmatizante que ofrecen a los usuarios de drogas inyectables. La confianza que se establece con los profesionales y la importancia de los pares ha sido también destacada. Sin embargo, persisten las dificultades anteriores que presenta el sistema de atención estándar.
Discusión: La colocalización de la atención en sitios no estigmatizantes y una buena relación de confianza con los profesionales son centrales para la experiencia de navegación de quienes se inyectan drogas con respecto a la profilaxis preexposición y a la atención de la hepatitis C. Es necesario llevar a cabo otros estudios para profundizar los factores personales y contextuales vinculados con la experiencia de navegación realizada por las personas que utilizan drogas inyectables.
Palabras clave:
- personas que utilizan drogas inyectables,
- servicios de navegación,
- profilaxis preexposición,
- atención de la hepatitis C,
- experiencias
Parties annexes
Bibliographie
- Alimohammadi, A., Holeksa, J., Thiam, A., Truong, D. et Conway, B. (2018). Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting. Open Forum Infectious Diseases, 5(6), N.PAG. Academic Search Complete. https://doi.org/10.1093/ofid/ofy120
- Arai, L., Britten, N., Popay, J., Roberts, H., Petticrew, M., Rodgers, M. et Sowden, A. (2007). Testing methodological developments in the conduct of narrative synthesis: A demonstration review of research on the implementation of smoke alarm interventions. Evidence & Policy: A Journal of Research, Debate and Practice, 3(3), 361‑383. https://doi.org/10.1332/174426407781738029
- Bajis, S., Grebely, J., Cooper, L., Smith, J., Owen, G., Chudleigh, A., Hajarizadeh, B., Martinello, M., Adey, S., Read, P., Gilliver, R., Applegate, T., Treloar, C., Maher, L. et Dore, G. J. (2019). Hepatitis C virus testing, liver disease assessment and direct‑acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study. Journal of Viral Hepatitis, jvh.13112. https://doi.org/10.1111/jvh.13112
- Batchelder, A. W., Brisbane, M., Litwin, A. H., Nahvi, S., Berg, K. M., & Arnsten, J. H. (2013). “Damaging what wasn’t damaged already”: Psychological tension and antiretroviral adherence among HIV-infected methadone-maintained drug users. AIDS Care, 25(11), 1370‑1374. https://doi.org/10.1080/09540121.2013.766303
- Batchelder, A. W., Cockerham-Colas, L., Peyser, D., Reynoso, S. P., Soloway, I. et Litwin, A. H. (2017). Perceived benefits of the hepatitis C peer educators: A qualitative investigation. Harm Reduction Journal, 14(1), 67. https://doi.org/10.1186/s12954-017-0192-8
- Bazzi, A. R., Drainoni, M.-L. ,Biancarelli, D. L., Hartman, J. J., Mimiaga, M. J., Biello, K. B. et Mayer, K. H. (2019). Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: Evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions 11 Medical and Health Sciences 1117 Public Health and Health Services. BMC Public Health, 19(1). Scopus®. https://doi.org/10.1186/s12889-018-6314-8
- Bernard, C. L., Owens, D. K., Goldhaber-Fiebert, J. D. et Brandeau, M. L. (2017). Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis. PLOS Medicine, 14(5), e1002312. https://doi.org/10.1371/journal.pmed.1002312
- Beyrer, C., Baral, S., Kerrigan, D., El-Bassel, N., Bekker, L.-G. et Celentano, D. D. (2011). Expanding the Space: Inclusion of Most-at-Risk Populations in HIV Prevention, Treatment, and Care Services. JAIDS Journal of Acquired Immune Deficiency Syndromes, 57(Supplement 2), S96‑S99. https://doi.org/10.1097/QAI.0b013e31821db944
- Biancarelli, D. L., Biello, K. B., Childs, E., Drainoni, M., Salhaney, P., Edeza, A., Mimiaga, M. J., Saitz, R. et Bazzi, A. R. (2019). Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug and Alcohol Dependence, 198, 80-86. https://doi.org/10.1016/j.drugalcdep.2019.01.037
- Biello, K. B., Bazzi, A. R., Mimiaga, M. J., Biancarelli, D. L., Edeza, A., Salhaney, P., Childs, E. et Drainoni, M. L. (2018). Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduction Journal, 15(1), 55. https://doi.org/10.1186/s12954-018-0263-5
- Biello, K. B., Bazzi, A. R., Vahey, S., Harris, M., Shaw, L. et Brody, J. (2021). Delivering Preexposure Prophylaxis to People Who Use Drugs and Experience Homelessness, Boston, MA, 2018–2020. American Journal of Public Health, 111(6), 1045‑1048. https://doi.org/10.2105/AJPH.2021.306208
- Blackstock, O. J., Platt, J., Golub, S. A., Anakaraonye, A. R., Norton, B. L., Walters, S. M., Sevelius, J. M. et Cunningham, C. O. (2021). A Pilot Study to Evaluate a Novel Pre-exposure Prophylaxis Peer Outreach and Navigation Intervention for Women at High Risk for HIV Infection. AIDS and Behavior, 25(5), 1411‑1422. https://doi.org/10.1007/s10461-020-02979-y
- Bonnington, O. et Harris, M. (2017). Tensions in relation : How peer support is experienced and received in a hepatitis C treatment intervention. International Journal of Drug Policy, 47, 221‑229. https://doi.org/10.1016/j.drugpo.2017.05.031
- Brener, L., Horwitz, R., von Hippel, C., Bryant, J. et Treloar, C. (2015). Discrimination by health care workers versus discrimination by others: Countervailing forces on HCV treatment intentions. Psychology, Health & Medicine, 20(2), 148‑153. https://doi.org/10.1080/13548506.2014.923103
- Brener, L., Cama, E., Broady, T., Hopwood, M., de Wit, J. et Treloar, C. (2019). Predictors of health care workers’ support for discriminatory treatment and care of people who inject drugs. Psychology, Health & Medicine, 24(4), 439‑445. https://doi.org/10.1080/13548506.2018.1546018
- Bruneau, J., Roy, É., Demers, N. et Cox, J. (2016). Some PWID communities are ready for PrEP, so what is next? Addiction, 112(4), 582‑584. https://doi.org/10.1111/add.13686
- Carlberg-Racich, S. (2016). Harm reduction interventions in HIV care: A qualitative exploration of patient and provider perspectives. Peerj, 4, e1932‑e1932. https://doi.org/10.7717/peerj.1932
- Carter, N., Valaitis, R. K., Lam, A., Feather, J., Nicholl, J. et Cleghorn, L. (2018). Navigation delivery models and roles of navigators in primary care: A scoping literature review. BMC Health Services Research, 18(1), 96. https://doi.org/10.1186/s12913-018-2889-0
- Centers for Disease control (CDC). (2019). Fast facts: HIV and injection drug use.https://www.cdc.gov/hiv/pdf/risk/cdc-hiv-idu-fact-sheet.pdf
- Chang, J., Dubbin, L., & Shim, J. (2016). Negotiating substance use stigma: The role of cultural health capital in provider-patient interactions. Sociology of Health & Illness, 38(1), 90‑108. https://doi.org/10.1111/1467-9566.12351
- Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., Chuachoowong, R., Gvetadze, R. J., McNicholl, J. M., Paxton, L. A., Curlin, M. E., Hendrix, C. W., & Vanichseni, S. (2013). Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 381(9883), 2083‑2090. https://doi.org/10.1016/S0140-6736(13)61127-7
- Coffin, P. O., Rowe, C. et Santos, G.-M. (2015). Novel Interventions to Prevent HIV and HCV Among Persons Who Inject Drugs. Current HIV/AIDS Reports, 12(1), 145‑163. https://doi.org/10.1007/s11904-014-0248-2
- Coleman, R. L. et McLean, S. (2016). Commentary: The value of PrEP for people who inject drugs. Journal of the International AIDS Society, 19(7 [Suppl 6]). https://doi.org/10.7448/IAS.19.7.21112
- Coupland, H., White, B., Bates, A., Park, J. N., Iversen, J. et Maher, L. (2019). Engaging people who inject drugs in hepatitis c virus testing and prevention through community-based outreach, in sydney, Australia. Drug and Alcohol Review, 38(2), 177–184. https://doi.org/10.1111/dar.12895
- Critical Appraisal Skills Programme. (2018). CASP Qualitative Research Checklist. https://casp-uk.net/wp-content/uploads/2018/03/CASP-Qualitative-Checklist-2018_fillable_form.pdf
- Crowley, D., Van, H. M. C., Lambert, J. S., Cullen, W., Murphy, C. et Kelly, E. (2018). Barriers and facilitators to hepatitis c (hcv) screening and treatment-a description of prisoners’ perspective. Harm Reduction Journal, 15(1). https://doi.org/10.1186/s12954-018-0269-z
- Degenhardt, L., Peacock, A., Colledge, S., Leung, J., Grebely, J., Vickerman, P., Stone, J., Cunningham, E. B., Trickey, A., Dumchev, K., Lynskey, M., Griffiths, P., Mattick, R. P., Hickman, M. et Larney, S. (2017). Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs : A multistage systematic review. The Lancet Global Health, 5(12), e1192‑e1207. https://doi.org/10.1016/S2214-109X(17)30375-3
- Demchenko, I., Kozhan, N., & Varban, M. (2014). The Study of Access to HIV and TB Treatment for Substitution Therapy Patients Within Different Service Delivery Models. International HIV/AIDS Alliance in Ukraine. https://aph.org.ua/wp-content/uploads/2016/08/ZPT_engl.pdf
- Drainoni, M.-L., Farrell, C., Sorensen-Alawad, A., Palmisano, J. N., Chaisson, C. etWalley, A. Y. (2014). Patient Perspectives of an Integrated Program of Medical Care and Substance Use Treatment. AIDS Patient Care and STDs, 28(2), 71‑81. https://doi.org/10.1089/apc.2013.0179
- Earnshaw, V., Smith, L., & Copenhaver, M. (2013). Drug Addiction Stigma in the Context of Methadone Maintenance Therapy: An Investigation into Understudied Sources of Stigma. International Journal of Mental Health and Addiction, 11(1), 110‑122. https://doi.org/10.1007/s11469-012-9402-5
- Fadnes, L. T., Aas, C. F., Vold, J. H., Leiva, R. A., Ohldieck, C., Chalabianloo, F., Skurtveit, S., Lygren, O. J., Dalgård, O., Vickerman, P., Midgard, H., Løberg, E.M., Johansson, K. A. et INTRO-HCV Study Group. (2021). Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). PLoS medicine, 18(6), e1003653. https://doi.org/10.1371/journal.pmed.1003653
- Felsher, M., Ziegler, E., Smith, L. R., Sherman, S. G., Amico, K. R., Fox, R., Madden, K., & Roth, A. M. (2020). An Exploration of Pre-exposure Prophylaxis (PrEP) Initiation Among Women Who Inject Drugs. Archives of Sexual Behavior, 49(6), 2205‑2212. https://doi.org/10.1007/s10508-020-01684-0
- Foley, V., Petit, G., Giraud, M., Boisvert, K., Rietmann, M. et Brousselle, A. (2016). Hépatite C chez les usagers de drogues par voie veineuse : exploration des barrières et des facilitants pour l’accès aux soins et services. Santé Publique, 28, 363-374. https://doi.org/10.3917/spub.163.0363
- Freeman, H. P., & Rodriguez, R. L. (2011). History and principles of patient navigation. Cancer, 117(S15), 3537‑3540. https://doi.org/10.1002/cncr.26262
- Friedmann, P. D., Alexander, J. A., Jin, L., & D’Aunno, T. A. (1999). On-site primary care and mental health services in outpatient drug abuse treatment units. The Journal of Behavioral Health Services & Research, 26(1), 80‑94. https://doi.org/10.1007/BF02287796
- Giacomazzo, A., Kayti Ferguson, Hana Haines et Jennifer Isaacs, Chelsea Grothé, Thomas Hendsbee, & Jo Parker. (2022, mars). Health navigation services for people who use drugs / Services de navigation de la santé pour les personnes qui utilisent des drogues [Webinaire]. Services de navigation de la santé pour les personnes qui utilisent des drogues. https://www.catie.ca/fr/services-de-navigation-de-la-sante-pour-les-personnes-qui-utilisent-des-drogues
- Giacomazzo, A., & Challacombe, L. (2018). La navigation de la santé dans les services en VIH : Un examen des données probantes. https://www.catie.ca/fr/point-de-mire-sur-la-prevention/la-navigation-de-la-sante-dans-les-services-en-vih-un-examen-des
- Gonzalez, S. A., Fierer, D. S. et Talal, A. H. (2017). Medical and behavioral approaches to engage people who inject drugs into care for hepatitis c virus infection. Addictive Disorders & Their Treatment, 16(2 Suppl 1), 23. https://doi.org/10.1097/ADT.0000000000000104
- Grebely, J., Hajarizadeh, B., Lazarus, J. V., Bruneau, J. et Treloar, C. (2019). Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. International Journal of Drug Policy, 72, 1‑10. https://doi.org/10.1016/j.drugpo.2019.07.016
- Grebely, J., Tran, L., Degenhardt, L., Dowell-Day, A., Santo, T., Larney, S., Hickman, M., Vickerman, P., French, C., Butler, K., Gibbs, D., Valerio, H., Read, P., Dore, G. J. et Hajarizadeh, B. (2021). Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis c infection among people who inject drugs: a systematic review and metaanalysis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 73(1), 118. https://doi.org/10.1093/cid/ciaa612
- Grimshaw, C., Boyd, L., Smith, M., Estcourt, C. S. et Metcalfe, R. (2021). Evaluation of an inner city hiv pre-exposure prophylaxis service tailored to the needs of people who inject drugs. Hiv Medicine, 22(10), 965–970. https://doi.org/10.1111/hiv.13181
- Guise, A., Seguin, M., Mburu, G., McLean, S., Grenfell, P., Islam, Z., Filippovych, S., Assan, H., Low, A., Vickerman, P. et Rhodes, T. (2017). Integrated opioid substitution therapy and HIV care: A qualitative systematic review and synthesis of client and provider experiences. AIDS Care, 29(9), 1119‑1128. https://doi.org/10.1080/09540121.2017.1300634
- Gunn, J., & Higgs, P. (2019). Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study. Research In Social & Administrative Pharmacy: RSAP. https://doi.org/10.1016/j.sapharm.2019.04.004
- Harris, M., Roberts, K., Bonnington, O., Harrison, G., Hickman, M., Irving, W., Waldron, C. A., Bevan, J., Simpson, C., Homan, C., Reeve, D., Hathaway, C., Purcell, S., Oelbaum, S., Whitfield, J., Jennings, S., Dreha, R., Byrne, T., Thomas, D., … HepCATT team. (2018). Understanding hepatitis c intervention success-qualitative findings from the HEPCATT study. Journal of Viral Hepatitis, 25(7), 762–770. https://doi.org/10.1111/jvh.12869
- Harris, M., Jolly, E., Martin, A., Wells, H., & Rhodes, T. (2012). Barriers and facilitators to hepatitis C treatment for people who inject drugs [Technical Report]. World Health Organization for Europe Region. https://researchonline.lshtm.ac.uk/id/eprint/2551684
- Hemmy Asamsama, O., Squires, L., Tessema, A., Rae, E., Hall, K., Williams, R., & Benator, D. (2017). HIV Nurse Navigation: Charting the Course to Improve Engagement in Care and HIV Virologic Suppression. Journal of the International Association of Providers of AIDS Care (JIAPAC), 16(6), 603‑607. https://doi.org/10.1177/2325957417732835
- Hershow, R. B., Gonzalez, M., Costenbader, E., Zule, W., Golin, C. et Brinkley-Rubinstein, L. (2019). Medical providers and harm reduction views on pre-exposure prophylaxis for hiv prevention among people who inject drugs. Aids Education and Prevention, 31(4), 363–379. https://doi.org/10.1521/aeap.2019.31.4.363
- Islam, M. M., Topp, L., Day, C. A., Dawson, A. et Conigrave, K. M. (2012). The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: a narrative synthesis of literature. International Journal of Drug Policy, 23(2), 94-102. https://doi.org/10.1016/j.drugpo.2011.08.005
- Jacob, J., Ti, L., & Knight, R. (2021). Will peer-based interventions improve hepatitis C virus treatment uptake among young people who inject drugs? Canadian Journal of Public Health, 112(3), 460‑463. https://doi.org/10.17269/s41997-020-00413-3
- Jennifer Edelman, E., Moore, B. A., Berkenblit, G., Calabrese, S., Cunningham, C., Fiellin, D. A., Patel, V., Phillips, K. A., Tetrault, J., Shah, M. et Blackstock, O. (2017). Hiv pre-exposure prophylaxis for people who inject drugs: willingness to prescribe among general internists. Drug and Alcohol Dependence, 171, 58. https://doi.org/10.1016/j.drugalcdep.2016.08.170
- Jo, Y., Bartholomew, T. S., Doblecki-Lewis, S., Rodriguez, A., Forrest, D. W., Tomita-Barber, J., Oves, J. etTookes, H. E. (2020). Interest in linkage to PrEP among people who inject drugs accessing syringe services, Miami, Florida. PLoS ONE, 15(4), 1-1‑12. https://doi.org/10.1371/journal.pone.0231424
- Koester, K. A., Morewitz, M., Pearson, C., Weeks, J., Packard, R., Estes, M., Tulsky, J., Kang-Dufour, M. et Myers, J. J. (2014). Patient Navigation Facilitates Medical and Social Services Engagement Among HIV‑Infected Individuals Leaving Jail and Returning to the Community. AIDS Patient Care and STDs, 28(2), 82‑90. https://doi.org/10.1089/apc.2013.0279
- Leclerc, P., Roy, E., Morisette, C., & Blouin, K. (2018). Surveillance des maladies infectieuses chez les utilisateurs de drogues par injection—Épidémiologie du VIH 1995-2017 : Épidémiologie du VHC 2003-2017(p. 4). INSPQ. https://www.inspq.qc.ca/sites/default/files/publications/2516_surveillance_maladies_infectieuses_utiisateurs_drogue_injection.pdf
- Lin, C., Cao, X. et Li, L. (2014). Integrating antiretroviral therapy in methadone maintenance therapy clinics: Service provider perceptions. International Journal of Drug Policy, 25(6), 1066‑1070. https://doi.org/10.1016/j.drugpo.2014.04.021
- Loignon, C., Dupéré, S., Benhadj, L., Carru, D., & Dahrouge, S. (2022). Perspectives of structurally marginalised patients attending contextually tailored and integrated care practices in Canada: A focused ethnography study. BMJ Open, 12(5), e056133. https://doi.org/10.1136/bmjopen-2021-056133
- MacArthur, G. J., van Velzen, E., Palmateer, N., Kimber, J., Pharris, A., Hope, V., Taylor, A., Roy, K., Aspinall, E., Goldberg, D., Rhodes, T., Hedrich, D., Salminen, M., Hickman, M. et Hutchinson, S. J. (2014). Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. International Journal of Drug Policy, 25(1), 34‑52. https://doi.org/10.1016/j.drugpo.2013.07.001
- MacLellan, J., Surey, J., Abubakar, I., Stagg, H. R. et Mannell, J. (2017). Using peer advocates to improve access to services among hard-to-reach populations with hepatitis c: a qualitative study of client and provider relationships. Harm Reduction Journal, 14(1), 76-76. https://doi.org/10.1186/s12954-017-0202-x
- Magdalena, H., Jolly, E., Martin, A., Wells, H., & Rhodes, T. (2012). Barriers and facilitators to hepatitis C treatment for people who inject drugs [Technical Report]. World Health Organization for Europe Region. https://researchonline.lshtm.ac.uk/id/eprint/2551684
- Marshall, B. D. L. et Milloy, M.-J. (2016). Improving the effectiveness and delivery of pre-exposure prophylaxis (PrEP) to people who inject drugs: commentaries. Addiction, 112(4), 580-582. https://doi.org/10.1111/add.13597
- Mason, K., Dodd, Z., Sockalingam, S., Altenberg, J., Meaney, C., Millson, P., & Powis, J. (2015). Beyond viral response: A prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support. The International journal on drug policy, 26(10), 1007‑1013. https://doi.org/10.1016/j.drugpo.2015.04.012
- Miller, K., Treloar, C. et Lloyd, A. R. (2021). People in prison who inject drugs: Who is trusted when it comes to information about hepatitis C? Addiction Research & Theory, 29(3), 247‑254. https://doi.org/10.1080/16066359.2021.1879058
- Mistler, C. B., Copenhaver, M. M. et Shrestha, R. (2021). The Pre-exposure Prophylaxis (PrEP) Care Cascade in People Who Inject Drugs : A Systematic Review. AIDS and Behavior, 25(5), 1490‑1506. https://doi.org/10.1007/s10461-020-02988-x
- Morgan, K., Lee, J. et Sebar, B. (2015). Community health workers: A bridge to healthcare for people who inject drugs. International Journal of Drug Policy, 26(4), 380‑387. https://doi.org/10.1016/j.drugpo.2014.11.001
- Muncan, B., Walters, S. M., Ezell, J. et Ompad, D. C. (2020). “They look at us like junkies”: Influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduction Journal, 17(1), 53. https://doi.org/10.1186/s12954-020-00399-8
- Muncan, B., Jordan, A. E., Perlman, D. C., Frank, D., Ompad, D. C. et Walters, S. M. (2021). Acceptability and Effectiveness of Hepatitis C Care at Syringe Service Programs for People Who Inject Drugs in New York City. Substance Use & Misuse, 56(5), 728‑737. https://doi.org/10.1080/10826084.2021.1892142
- Nazari, S. S. H., Noroozi, M., Soori, H., Noroozi, A., Mehrabi, Y., Hajebi, A., Sharifi, H., Higgs, P., & Mirzazadeh, A. (2016). The effect of on-site and outreach-based needle and syringe programs in people who inject drugs in Kermanshah, Iran. International Journal of Drug Policy, 27, 127‑131.https://doi.org/10.1016/j.drugpo.2015.10.011
- Ostertag, S., Wright, B. R. E., Broadhead, R. S. et Altice, F. L. (2006). Trust and other characteristics associated with health care utilization by injection drug users. Journal of Drug Issues, 36(4), 953-974. https://doi.org/10.1177/002204260603600409
- Pagkas-Bather, J., Jaramillo, J., Henry, J., Grandberry, V., Ramirez, L. F., Cervantes, L., Stekler, J. D., Andrasik, M. P., & Graham, S. M. (2020). What’s PrEP?: Peer navigator acceptability among minority MSM in Washington. BMC Public Health, 20(1), 248. https://doi.org/10.1186/s12889-020-8325-5
- Paquette, C. E., Syvertsen, J. L. et Pollini, R. A. (2018). Stigma at every turn: health services experiences among people who inject drugs. International Journal of Drug Policy, 57, 104-110. https://doi.org/10.1016/j.drugpo.2018.04.004
- Perreault, M., & Poliquin, H. (2018). Significations de la santé et du prendre soin de soi pour des personnes qui font usage de drogues par injection et perspectives de ces dernières sur ce qui pourrait être fait pour leur permettre de mieux prendre soin d’elles-mêmes [Université de Sherbrooke]. WorldCat.org. http://hdl.handle.net/11143/15030
- Phillips, C., Schulkind, J., O’Sullivan, M., Edelman, N., Smith, H. E., Verma, S. et Jones, C. J. (2019). Improving access to care for people who inject drugs: Qualitative evaluation of project ITTREAT-An integrated community hepatitis C service. Journal Of Viral Hepatitis. https://doi.org/10.1111/jvh.13214
- Platt, L., Easterbrook, P., Gower, E., McDonald, B., Sabin, K., McGowan, C., Yanny, I., Razavi, H. et Vickerman, P. (2016). Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and metaanalysis. The Lancet Infectious Diseases, 16(7), 797‑808. https://doi.org/10.1016/S1473-3099(15)00485-5
- Popay, J., Roberts, H., Sowden, A., Petticrew, M., Arai, L., Rodgers, M., Britten, N., Roen, K. et Duffy, S. (2006). Guidance on the conduct of narrative synthesis in systematic reviews: A product from the ESRC Methods Programme. Lancaster University. https://doi.org/10.13140/2.1.1018.4643
- Rose, R., Cross, S., Lamers, S. L., Astemborski, J., Kirk, G. D., Mehta, S. H., Sievers, M., Martens, C., Bruno, D., Redd, A. D., & Laeyendecker, O. (2020). Persistence of HIV transmission clusters among people who inject drugs. AIDS, 34(14), 2037‑2044. https://doi.org/10.1097/QAD.0000000000002662
- Roth, A. M., Tran, N. K., Felsher, M., Gadegbeku, A. B., Piecara, B., Fox, R., Krakower, D. S., Bellamy, S. L., Amico, K. R., Benitez, J. A. et Van Der Pol, B. (2021). Integrating hiv preexposure prophylaxis with community-based syringe services for women who inject drugs: results from the project she demonstration study. Journal of Acquired Immune Deficiency Syndromes (1999), 86(3), 70. https://doi.org/10.1097/QAI.0000000000002558
- Sherbuk, J. E., Tabackman, A., McManus, K. A., Kemp Knick, T., Schexnayder, J., Flickinger, T. E. et Dillingham, R. (2020). A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South. Harm Reduction Journal, 17(1), 64. https://doi.org/10.1186/s12954-020-00409-9
- Shrestha, R. et Copenhaver, M. (2018). Exploring the Use of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among High-Risk People Who Use Drugs in Treatment. Frontiers in Public Health, 6, 195. https://doi.org/10.3389/fpubh.2018.00195
- Shrestha, R., Altice, F. L., Karki, P. et Copenhaver, M. M. (2018). Integrated Biobehavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study. AIDS And Behavior, 22(8), 2640‑2649. https://doi.org/10.1007/s10461-018-2099-0
- Shrestha, R., Altice, F. L., DiDomizio, E., Sibilio, B., Ranjit, Y. S. et Copenhaver, M. M. (2020). Feasibility and Acceptability of an mHealth-Based Approach as an HIV Prevention Strategy Among People Who Use Drugs on Pre-Exposure Prophylaxis. Patient Preference and Adherence, 14, 107-118. https://doi.org/10.2147/PPA.S236794
- Smith, M., Elliott, L., Hutchinson, S. J., Metcalfe, R., Flowers, P. et McAuley, A. (2021). Perspectives on pre-exposure prophylaxis for people who inject drugs in the context of an hiv outbreak: a qualitative study. The International Journal on Drug Policy, 88, 103033–103033. https://doi.org/10.1016/j.drugpo.2020.103033
- Spector, A. Y., Remien, R. H., & Tross, S. (2015). PrEP in substance abuse treatment: A qualitative study of treatment provider perspectives. Substance Abuse Treatment, Prevention & Policy, 10(1), 1‑19. a9h. https://doi.org/10.1186/1747-597X-10-1
- Stevens, E. R., Nucifora, K. A., Uyei, J., Scott, B. R., Hagan, H., des, J. D., Jordan, A. E., Khan, B. et Dombrowski, K. (2020). Cost-effectiveness of direct antiviral agents for hepatitis c virus infection and a combined intervention of syringe access and medication-assisted therapy for opioid use disorders in an injection drug use population. Clinical Infectious Diseases, 70(12), 2652–2662. https://doi.org/10.1093/cid/ciz726
- Tarasuk, J., Zhang, J., Lemyre, A., Cholette, F., Bryson, M., & Paquette, D. (2020). Résultats nationaux de l’enquête Track auprès des utilisateurs de drogues injectables au Canada, phase 4, 2017 à 2019. Relevé des maladies transmissibles au Canada, 155‑168. https://doi.org/10.14745/ccdr.v46i05a07f
- Ti, L., Hayashi, K., Hattirat, S., Suwannawong, P., Kaplan, K. et Kerr, T. (2015). “Drug users stick together”: HIV testing in peer-based drop-in centres among people who inject drugs in Thailand. Sexual Health, 12(3), 263. https://doi.org/10.1071/SH14107
- Treloar, C., Rance, J., Dore, G. J., Grebely, J. et the ETHOS Study Group. (2013). Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: Insights from the ETHOS study. Journal of Viral Hepatitis, 21(8), 560‑567. https://doi.org/10.1111/jvh.12183
- Treloar, C., Rance, J., Bath, N., Everingham, H., Micallef, M., Day, C., Hazelwood, S., Grebely, J. et Dore, G. J. (2015). Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. International Journal of Drug Policy, 26(10), 992‑998. https://doi.org/10.1016/j.drugpo.2015.01.005
- United Nations Office on Drugs and Crime, United Nations Office on Drugs and Crime, International Network of People Who Use Drugs, Joint, United Nations Programme on HIV/AIDS, United Nations Development Programme, United Nations, & Population Fund, World Health Organization, United States Agency for International Development. (2017). Implementing comprehensive HIV and HCV programmes with people who inject drugs: Practical guidance for collaborative interventions. Vienna: United Nations Office on Drugs and Crime. https://www.undp.org/publications/implementing-comprehensive-hiv-and-hcv-programmes-people-who-inject-drugs
- Valaitis, R. K., Carter, N., Lam, A., Nicholl, J., Feather, J. et Cleghorn, L. (2017). Implementation and maintenance of patient navigation programs linking primary care with community-based health and social services: A scoping literature review. BMC Health Services Research, 17(1), 116. https://doi.org/10.1186/s12913-017-2046-1.
- Walters, S. M., Frank, D., Van Ham, B., Jaiswal, J., Muncan, B., Earnshaw, V., Schneider, J., Friedman, S. R. et Ompad, D. C. (2022). PrEP Care Continuum Engagement Among Persons Who Inject Drugs: Rural and Urban Differences in Stigma and Social Infrastructure. AIDS and Behavior. https://doi.org/10.1007/s10461-021-03488-2
- Wells, K. J., Valverde, P., Ustjanauskas, A. E., Calhoun, E. A., & Risendal, B. C. (2018). What are patient navigators doing, for whom, and where? A national survey evaluating the types of services provided by patient navigators. Patient Education and Counseling, 101(2), 285‑294. https://doi.org/10.1016/j.pec.2017.08.017
- World Health Organization. (2015). Policy brief: Pre-exposure prophylaxis (PrEP) : WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP). https://apps.who.int/iris/handle/10665/197906